Jump to:

Herceptin licensed as neoadjuvant-adjuvant therapy in early breast cancer

01 March 2012, 9:02am

The indications for Herceptin (trastuzumab) have been extended to include use in patients 65 years and younger in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for HER2 positive early breast cancer, that is locally advanced (including inflammatory) or where tumours are more than 2cm in diameter.

Herceptin (trastuzumab) is also licensed for metastatic breast cancer and certain gastrointestinal tumours

Herceptin (trastuzumab) is also licensed for metastatic breast cancer and certain gastrointestinal tumours

Clinical study

This licence extension follows results from the randomised, open-label NOAH trial in patients with newly diagnosed locally advanced or inflammatory early breast cancer. Patients were randomised to receive either neoadjuvant chemotherapy (including both an anthracycline and a taxane) plus trastuzumab followed by adjuvant trastuzumab monotherapy (n=117), or neoadjuvant chemotherapy alone (n=118).

In the study, trastuzumab (8mg/kg loading dose followed by 6mg/kg every 3 weeks) was administered concurrently with 10 cycles of neo-adjuvant chemotherapy, consisting of:

  • doxorubicin plus paclitaxel every 3 weeks for 3 cycles then;
  • paclitaxel every 3 weeks for 4 cycles then;
  • cyclophosphamide plus methotrexate plus 5-fluorouracil every 4 weeks for 3 cycles.

After surgery was completed, patients continued to receive 3-weekly cycles of trastuzumab to complete 1 year of treatment.


After a median follow-up of 3.2 years, the 3-year event-free survival was 71% in the trastuzumab plus chemotherapy group compared with 56% in the chemotherapy-only group.

Investigators observed total pathological complete response, defined as absence of invasive cancer in both breast and axillary nodes, in 38% of patients who received neoadjuvant chemotherapy plus trastuzumab compared with 19% of patients who received neoadjuvant chemotherapy alone (p=0.001).

View Herceptin drug record

Further Information: Roche Products Ltd


MIMS Specialist Journals

Now available on www.mims.co.uk

Click here to view

7-Part CME IBS Programme

Irritable bowel syndrome medical education programme worth 6.5 CPD credits. Click here to view

MIMS app

Access the full MIMS database from your mobile device

Click here to find out more

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Find drugs by:

Travel Vaccination & Malaria Advice

Travel Vaccination & Malaria Advice

Supplied by the National
Travel Health Network
and Centre (NaTHNaC)

Palliative Care Resources

Palliative Care Resources

Opioid dose conversions
and much more

Childhood Immunisation

Childhood Immunisation

Summary of routine
vaccination schedule

Referral Guidelines for Breast Disorders

Referral Guidelines for Breast Disorders

MIMS Summary of NHS Cancer Screening Referral Guidelines

Quick-reference table: antibiotics

Quick-reference table: antibiotics

Treatment regimens for common infections

Back to top